Abstract. The aberrant methylation of CpG islands is a common epigenetic alteration found in cancers. The process contributes to cancer formation through the transcriptional silencing of tumor suppressor genes. CpG island methylation has been observed in aberrant crypt foci (ACF) and adenomas in the colon, implicating it in the earliest aspects of colon cancer formation. In addition, some investigators have identified an age-related increase in DNA methylation of the ESR1 locus in the colon mucosa, suggesting that DNA methylation may be a pre-neoplastic change that increases the risk of colon adenomas and colon cancer. We investigated the methylation status in the promoter regions of the CDKN2A/p16, hMLH1, and MGMT genes in human nonneoplastic rectal mucosa and evaluated whether these methylation markers may predict the presence of adenomatous polyps in the colon. The promoter methylation patterns of these genes were examined in rectal biopsies (mucosa samples) of 97 colorectal adenoma cases and 94 healthy controls using methylation-specific PCR (MSP) assays. Methylation of the MGMT and hMLH1 genes was present in both cases and controls, with a frequency of 12.4% and 18.1% for the MGMT gene and 12.4% and 11.7% for the hMLH1 gene. The frequency of CDKN2A/p16 promoter methylation was very rare in normal colorectal tissue with a frequency of ~2%. Overall, no apparent case-control difference was identified in the methylation status of these genes, either alone or in combination. hMLH1 methylation was more frequently observed among overweight or obese subjects (BMI≥25) with an adjusted OR of 3.7 (95% CI=1.0-13.7). Methylated alleles of the hMLH1 and MGMT genes were frequently detected in normal rectal mucosa, while the frequency of CDKN2A/p16 methylation detected was very low. The methylation status of these genes in rectal mucosa biopsies detected by MSP assays may not distinguish between patients with and without adenomas in the colon.
Introduction
Methylation of cytosines within CpG islands in the 5' region of genes is associated with loss of gene expression via repression of transcription (1) (2) (3) . Several studies have demonstrated that certain tumor suppressor and DNA repair genes are often aberrantly hypermethylated and silenced in colorectal cancer and adenomatous polyps (3) (4) (5) (6) (7) . More specifically, O 6 -methylguanine-DNA methyltransferase (MGMT), the human DNA mismatch repair gene mutator L homologue 1 (hMLH1), and the cyclin-dependent kinase inhibitor 2A (CDKN2A/p16) are frequently methylated in the adenoma step of the adenomacarcinoma sequence (5, (8) (9) (10) . CpG island methylation of MGMT reduces MGMT expression and has been associated with K-ras mutations (9, (11) (12) (13) . The methylation status of hMLH1, which encodes a DNA mismatch repair protein, has been found to contribute to 75% of sporadic colorectal carcinomas that display the microsatellite instability (MSI) phenotype (14) . In addition, age-related methylation of hMLH1 has been observed in normal mucosa associated with the development of colon tumors (14) (15) (16) . Inactivation of CDKN2A/p16 by methylation leads to disruption of cell-cycle regulation, potentially providing a growth advantage for affected cells. Epigenetic CDKN2A/p16 inactivation has been observed in both adenomas and colorectal cancer (4, 5, 16, 17) . It has been consistently reported that the CpG islands of the hMLH1, MGMT and CDKN2A/p16 genes are frequently methylated in colorectal cancer at a rate of 10~20%, 26~38% and 28~55%, respectively (7, (14) (15) (16) . Intriguingly, in a recent study of colorectal cancer, Shen et al found that 50% of patients whose cancer had MGMT promoter methylation also had substantial MGMT promoter methylation in normal adjacent mucosa. This indicated that MGMT promoter methylation might occur early in multi-step carcinogenesis, even before the emergence of morphologic changes in colorectal mucosa (18, 19) . Limited data, however, are available on the methylation status of these genes in the non-neoplastic mucosa of patients with colorectal tumors, and the results from previous studies have been conflicting (4, 15, 20, 21) .
Carcinogenesis is a complex process, with multiple genetic or epigenetic alterations that provide tumor cells with a selective advantage to expand their clones. It is possible that multiple lesions may develop throughout the colorectal mucosa after years of carcinogenic insults. Because CpG island hypermethylation is an early event in colorectal tumorigenesis, some epigenetic alterations may be detectable in colorectal mucosa that is histologically normal but 'primed' to become dysplastic. We hypothesize that promoter methylation in the MGMT, hMLH1 and CDKN2A/p16 genes in normal mucosa may reflect an underlying predisposition to develop colon adenomas and would be more common in cases with adenomatous polyps than in controls. We evaluated this hypothesis using non-neoplastic rectal tissue from patients with and without adenomas.
Materials and methods

Study participants.
Colorectal adenoma cases and controls were participants in the Tennessee Colorectal Polyp Study, an ongoing colonoscopy-based case-control study being conducted in Nashville, Tennessee. Eligible participants were between 40 and 75 years old and were identified from patients scheduled for colonoscopy at the Vanderbilt University Hospital endoscopy suite and the Nashville campus of the Veteran's Affairs Tennessee Valley Health Care System. Patients with a prior history of inflammatory bowel disease, genetic colorectal cancer syndromes, or any cancer other than non-melanoma skin cancers, were excluded from our study. The study was approved by the institutional review boards of both hospitals and written informed consent was obtained from all participants. Eligible participants were asked to provide biological samples, including blood, urine, rectal biopsy tissue and polyp tissue. A telephone interview was also conducted to obtain information on lifestyle, medication use, demographics, and medical history. Participants included in this analysis were the first 100 adenoma cases who provided rectal biopsy samples and 100 polyp-free patients who were frequency-matched to cases by race (white/non-white), sex and age (within 5 years).
Sample collection and processing. Consenting participants presented for scheduled colonoscopy having fasted the previous day and undergone bowel preparation using either a polyethylene glycol or a sodium phosphate solution. Standard optical colonoscopy was performed on all participants, with polyp status being determined by the attending gastroenterologist. Any identified polyps were removed using biopsy forceps or snare techniques. Adenoma status was determined by an attending pathologist from standard H&E-stained slides. Four rectal pinch biopsies of non-neoplastic epithelium were obtained from the mid-rectum using jumbo biopsy forceps. One rectal biopsy was obtained from each of the four quadrants of the rectum. The rectal biopsies were immediately snap frozen and stored at -80˚C until DNA extraction. Bisulfite modification. Bisulfite modification was conducted based on the principle that bisulfite treatment of DNA converts unmethylated cytosine residues into uracil, whereas methylated cytosine residues remain unmodified (1, 5, 8) . Thus, methylated and unmethylated DNA sequences after bisulfite conversion can be distinguished using sequence-specific primers. Genomic DNA was modified with sodium bisulfite according to the Table I . Primer sequences and PCR conditions for methylation-specific PCR. 
a , unmethylated sequence; m, methylated sequence; b the sequence 5'-GCGGTCCCAAAAGGGTCAGT-3' was added each primer in the 5 end'.
method previously described by Herman JG et al with minor modifications (22) . Briefly, 150 ng of genomic DNA and 1 μg of salmon sperm DNA (Sigma) in a volume of 50 ml were denatured by NaOH (final concentration, 0.2 M) for 10 min at 37˚C. Thirty microliters of 10 mM hydroquinone (EM Science, Gibbstown, NJ) and 520 ml of 3 M sodium bisulfite (Mallinckrodt Baker Inc., Paris, KY) at pH 5.0, both freshly prepared, were added and mixed and samples were incubated under mineral oil at 53˚C for 16 h. Modified DNA was purified using the Wizard DNA purification resin according to the manufacturer's protocol (Promega, USA) and eluted into 50 μl of water. The DNA was then desulfonated with 0.2 M NaOH for 10 min at room temperature, followed by precipitation in 100% ethanol overnight at -80˚C following the addition of 17 μl of 10 M NH 4 AC and 40 μg of glycogen (Roche Diagnostics, Florence, SC). The samples were then centrifuged at 13,000 rpm for 20 min to pellet and were then washed with 70% ethanol. The samples were repelleted by centrifugation, air-dried and then resuspended in 30 μl UV-treated, distilled water. The samples were stored at -80˚C for up to 8 weeks until they were used. The set of known methylated and unmethylated control DNA samples used in the MSP assays was included in each round of bisulfite treatment.
Methylation specific PCR (MSP).
Methylation of the 5'-CpG promoter region of three genes, MGMT, hMLH1 and CDKN2A/p16, were determined by MSP. Forward and reverse primers were synthesized, which corresponded to the predicted sequence of methylated or unmethylated genomic DNA after sodium bisulfite treatment (Table I) . For each PCR run, a master mixture was prepared on ice with 1X PCR buffer; 4 mmol/l MgCl 2 ; 200 mmol/l dATP, dCTP, dGTP and dTTP; 200 nmol/l each primer; and 1 U of HotStarTaq DNA polymerase (Qiagen). Two μl of sodium bisulfite-treated DNA were added to 18 μl of PCR mixture. Thermocycling conditions used were: initial denaturation and hot start at 95˚C for 15 min; 40 cycles consisting of 30 sec at 92˚C, the specific annealing temperature for 30 sec and 30 sec at 72˚C, followed by a final extension at 72˚C for 10 min. Four control samples were included in each MSP assay run for both the methylated and unmethylated reactions and included the following: Human placental DNA (Sigma), CpGenome ® universal methylated human DNA (Intergen), a bisulfitetreated water control, and a no template control for crosscontamination assessment. MSP reactions were analyzed by electrophoresis on 2.5% agarose gels and the ethidium bromide-stained PCR products were imaged with a UV transilluminator. The samples were considered methylationpositive only when methylated PCR products were shown in gel electrophoresis regardless of the status of unmethylated PCR products. Methylation-negative was defined as amplified DNA that was shown only with unmethylated primers but not methylated primers. If both the methylated and unmethylated primers were negative, the quality of the DNA was assumed to be inadequate and a repeat experiment was performed. A result was final when both observations were in agreement. In the case of a discordant interpretation, the analysis was repeated on two further occasions and, if concordance was not obtained, the result was considered nonassessable at that locus. Of the 100 cases and 100 controls included in the study, methylation data were obtained from 97 cases and 94 controls. Statistical analysis. Statistical analyses were performed using SAS software (Version 9.1, SAS Institute, Cary, NC, USA). Chi-squared statistics and Fisher's exact test were used to evaluate case-control differences in the distribution of methylation status for the genes under study. A two-sided probability value of less than 0.05 was considered statistically significant. Multivariate logistic regression models were used to estimate odds ratios (ORs) and their 95% confidence intervals (95% CIs) as a measure of the strength of the association between methylation status and participant characteristics.
Results
Comparisons of selected demographic and descriptive characteristics of study participants are shown in Table II . Approximately 50% of the cases were older than 60 years of age at diagnosis. Consistent with the frequency-matching, cases and controls were similar in age, sex, study location and purpose of colonoscopy.
The methylation distribution of the MGMT, hMLH1, and CDKN2A/p16 genes in cases and controls are presented in Table III . Preliminary results indicate that methylation of the CDKN2A/p16 promoter was rare; approximately 2% in both cases and controls; therefore, only methylation of the hMLH1 and MGMT genes was included in the final assay. Methylation of the hMLH1 and MGMT genes was present in the non-neoplastic rectal mucosa from both cases and controls. However, Table II . Demographic and descriptive characteristics of study participants.
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Total (n=97) hMLH1 and MGMT methylation ----------------------------------------------------------------------------------------------------- the case-control difference was not statistically significant in analyses performed for either a single gene or the combination of both genes. Table IV contains the results of the evaluation of the methylation status of the MGMT and hMLH1 genes in relation to the clinicopathological features of the cases. Only 3 cases were found to have both the MGMT and hMLH1 genes methylated in their rectal mucosa, and all three of them had multiple and/or advanced adenomas. Perhaps due to a small sample size, none of the comparisons presented in Table IV was statistically significant.
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The associations of gene methylation with some colorectal adenoma risk factors are summarized in Table V . Because no case-control differences were found in methylation, cases and controls were combined for these analyses. hMLH1 gene methylation tended to be more frequently observed among subjects who were older (OR=1.8, 95% CI: 0.5-6.5 for >70 years), drank alcoholic beverages regularly (OR=2.4, 95% CI: 0.8-6.7), or had a high BMI (OR=3.9, 95% CI: 1.0-14.7).
MGMT methylation status was positively associated with smoking status (OR=2.0, 95% CI: 0.6-6.7). However, the associations were not statistically significant, with the exception of the association of hMLH1 gene methylation with BMI.
Discussion
Epigenetic gene silencing is increasingly being recognized as a common mechanism through which cancer cells can inactivate tumor suppressor genes (2) . However, only a few previous studies have evaluated the methylation status of non-neoplastic tissue in adenoma patients and normal controls. In a study of 64 colorectal adenomas, hMLH1 was not detected in any paired normal colon tissues of adenomas (23) . In a study with 24 normal colon epithelia and 95 colon adenomas, Lee et al found that methylation of MGMT was present in 21.1% of adenomas (4) . However, the same study reported that hMLH1 methylation was rarely present in adenoma tissue (1.1%) and was not at all present in normal controls. In another study in ONCOLOGY REPORTS 16: 429-435, 2006 Table V. Association of hMLH1 and MGMT methylation status with selected demographic and lifestyle factors for adenoma risk. 
a Adjusted for sex, study site and case-control status; b adjusted for age, study site and case-control status; c adjusted for age, sex, study site and case-control status.
-
which 34 controls with a normal colonoscopic examination were assayed, neither hMLH1 nor MGMT gene methylation was detected (24) . In contrast to all of these studies, we found a relatively high rate of methylation of both the hMLH1 and MGMT genes in the rectal mucosa of cases and controls. We believe the higher frequency of methylation is a result of the sensitivity of the assay we employed to detect methylation. The MSP assays we employed can detect small clonal populations that would likely be below the detection threshold with other methylation assays (25) . Methylation of these genes, however, was not related to the presence or absence of an adenoma in the colon or rectum. CDKN2A/p16 showed infrequent methylation in both case and control tissue, as has been reported previously (4, 15, 17) , indicating that CDKN2A/p16 gene methylation is a rare event in the normal colorectal epithelium of adenoma patients.
Several previous studies evaluated the relationship between methylation and other clinicopathological characteristics of adenomas (1, 4, 5, 24) . Age has been reported to affect methylation overall and in a tissue-specific manner (4, 15) . Consistent with these reports, we found a suggestive, although nonsignificant increase in hMLH1 methylation with increasing age, and no association between age and MGMT methylation. Gene methylation status in adenoma tissues has also been associated with the adenoma's size (25) , histology (5), and degree of atypia (26) . In our study, we evaluated gene methylation status in normal rectal mucosa and found no association with adenoma characteristics. Another salient finding of our analysis was the higher frequency of hMLH1 methylation among subjects who were overweight or obese (BMI≥25). To our knowledge, this study is the first to report an association between overweight/obesity and an increased frequency of hMLH1 methylation. These results are interesting and warrant investigation in future studies with a larger sample size.
Overall, this study provides little evidence that analysis of the methylation status of MLH1, MGMT, or CDKN2A/p16 in non-neoplastic rectal mucosa will have substantial utility in predicting the presence of adenomas in the colorectum. Although the controls included in this study were all polypfree, as confirmed by colonoscopy, some of them may have been at a higher risk for neoplasm because they were referred for active symptoms and were, thus, more likely to be referred for a colonoscopy. This may reduce the case-control difference in gene methylation (6, 14) . However, more than 50% of our controls had a colonoscopy simply for screening purposes. The MSP method used in this study can, in theory, detect the presence of methylation at the 0.1% level (27) . However, this method only measures qualitative differences in methylation and it is possible that there are important quantitative differences between cases and controls that we were unable to identify. This issue also exists in almost all previous studies of methylation biomarkers (1, 4, 5, 28) . Our study was limited to individuals between the ages of 45 and 75. If differences are most salient at very young ages or very old ages, we were not able to evaluate these. It is also possible that the genes we assessed are not accurate indicators of early aberrant methylation. In fact, other authors have shown that other genes, such as CRBP1, CDH13, and MINT31, are aberrantly methylated in ACFs, and these may have been more appropriate genes to have assessed in non-neoplastic tissues (29) . Although this is the largest methylation study of nonneoplastic rectal epithelia, the statistical power was limited and could only detect a strong association. However, for a marker of meaningful clinical significance, the OR should be 3.0 or above, and this study should have 80% power to detect such an association.
In summary, we found little difference in the promoter methylation status of the hMLH1, MGMT, and CDK2NA/p16 genes in non-neoplastic rectal epithelium between patients with and without adenomas. These results suggest that the methylation status of these genes in rectal mucosa is unlikely to be a useful biomarker to predict the presence of colorectal adenomas.
